The US Department of Health and Human Services (HHS) has unveiled a sweeping roadmap to expedite drug research, from early-stage investigational studies through to late-stage trials.
The initiative, named Operation TrialBlazer, spans the FDA, NIH, ARPA-H, the Office of the Inspector General and the Office of the National Coordinator for Health Information Technology (ONC), reflecting how broadly HHS wants to reshape the path from discovery to first-in-human testing.
The roadmap is framed as a direct response to China's growing lead in clinical research. In 2024, China registered more than 7100 trials, accounting for 39% of the global total and overtaking the US for the first time.
Its discovery-to-IND cycle is now 50-70% faster than the rest of the world and if current trends continue, the FDA projects Chinese-developed drugs could account for 35% of FDA approvals by 2040.
Currently, the average time from a Pre-IND meeting request to IND submission in the US is 380 days, with a range stretching to almost 700 days.
The FDA says its new reforms, which, by its own estimate, are worth six to twelve months of saved development time, are designed to compress that timeline without lowering the regulatory bar on safety.
For pharmaceutical manufacturers, there are six main points to be aware of in the new roadmap.
1) CMC requirements are being explicitly loosened for Phase I
The FDA released a webpage targeting "common Phase I CMC data misconceptions," in which it calls out sponsors for submitting six months (or more) of stability data when only enough to cover the proposed trial duration is needed by the regulator.
It added that those who submit commercial-scale process details or exhaustive impurity profiling were not required to do so, saying, "a fully developed and validated commercial process is unnecessary at this stage."
It said these new, streamlined CMC data requirements should prevent sponsors and CDMOs from over-engineering early submissions, thereby accelerating trial initiation while maintaining patient safety.
2) "Prior knowledge" reuse — platform manufacturing data can now be recycled across products
The FDA said it plans to allow sponsors to reuse manufacturing/testing data from one product to support the next, provided methods are standardised and well understood.
It has already issued draft guidance specifically on leveraging prior knowledge for cell and gene therapy — a move that is important for platform-based CDMOs and CGT manufacturers, as it will mean less redundant validation work per product.
3) ARPA-H's ENGINE and UNICORN programmes: AI for advanced therapy manufacturing
The new guidance introduces the new ENGINE and UNICORN programmes from ARPA-H, which are aimed squarely at biomanufacturing.
The pair are AI-enabled tools to reduce batch variability and failure rates, improve product quality and better predict long-term outcomes for cell and gene therapies.
ARPA-H will also explore how they can be used to develop more standardised methods for complex/individualised therapies, an area where manufacturing pathways have historically been highly bespoke.
4) Reduced animal testing via risk-based nonclinical approach & NAMs
The FDA wants to eliminate "unnecessary animal toxicology studies," arguing they can add to drug development timelines without meaningfully protecting Phase I participants.
As an example of the scale involved, it noted that developing a monoclonal antibody can currently require hundreds of animals for pharmacology and toxicology testing alone.
Instead, it proposes a "science-driven risk-based" approach, using three new/recent draft guidances: monoclonal antibody streamlined nonclinical safety (Dec 2025), general NAMs guidance (March 2026) and oncology biologics/conjugates streamlined nonclinical safety (May 2026).
The agency described this as a "Weight of Evidence" approach, which could mean smaller, cheaper toxicology programmes feeding into manufacturing/release testing strategy.
5) Expedited-IND Acceleration Pilot: a new role for CROs/CDMOs
A new network of "Qualified Research Institutions" (academic medical centres, healthcare networks, CROs and regulatory advisors) will review IND components, including the CMC section, on a rolling basis alongside the FDA.
Sponsors will retain full ownership of their IND, but the pilot effectively inserts a new advisory layer ahead of formal submission, via a real-time rolling review platform that lets FDA assess QRI recommendations before the full application lands.
But, for CDMOs and regulatory consultancies, this does raise a question: how will a third-party pre-review sit alongside existing sponsor relationships and in-house regulatory teams?
6) A revised Master Protocols draft guidance
The agency hopes that a revised draft guidance on master protocols will encourage single, overarching trial structures that govern multiple sub-studies — potentially spanning different products, patient populations, or both.
By coordinating several investigations under a single framework, the FDA argues that this can reduce duplicative infrastructure and accelerate evidence generation, which has relevance to multi-product manufacturing planning and supply chain for CDMOs running parallel programmes.
Key takeaways for manufacturers
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
